The Experts below are selected from a list of 39774 Experts worldwide ranked by ideXlab platform
Abraham Morgentaler - One of the best experts on this subject based on the ideXlab platform.
-
recommendations on the diagnosis treatment and monitoring of Hypogonadism in men
The Aging Male, 2015Co-Authors: Bruno Lunenfeld, Michael Zitzmann, George Mskhalaya, Stefan Arver, Svetlana Kalinchenko, Yuliya Tishova, Abraham MorgentalerAbstract:Hypogonadism or Testosterone Deficiency (TD) in adult men as defined by low levels of serum testosterone accompanied by characteristic symptoms and/or signs as detailed further on can be found in long-recognized clinical entities such as Klinefelter syndrome, Kallmann syndrome, pituitary or testicular disorders, as well as in men with idiopathic, metabolic or iatrogenic conditions that result in testosterone deficiency. These recommendations do not encompass the full range of pathologies leading to Hypogonadism (testosterone deficiency), but instead focus on the clinical spectrum of Hypogonadism related to metabolic and idiopathic disorders that contribute to the majority of cases that occur in adult men.
-
systematic literature review of the risk factors comorbidities and consequences of Hypogonadism in men
Journal of Andrology, 2014Co-Authors: V Zarotsky, Mingyi Huang, W Carman, Abraham Morgentaler, Puneet K Singhal, D Coffin, T H JonesAbstract:Summary The objective of this review was to summarize the literature on the risk factors, comorbidities, and consequences of male Hypogonadism, which is defined as a syndrome complex that includes biochemical confirmation of low testosterone (T) and the consistent symptoms and signs associated with low T. A systematic literature search was performed in PubMed/MEDLINE, EMBASE, Cochrane Library for articles published in the last 10 years on risk factors, comorbidities, and consequences of male Hypogonadism. Of the 53 relevant studies identified, nine examined potential risk factors, 14 examined potential comorbidities, and 30 examined potential consequences of male Hypogonadism. Based on studies conducted in Asia, Australia, Europe, and North & South America, the important factors that predicted and correlated with Hypogonadism were advanced age, obesity, a diagnosis of metabolic syndrome (MetS), and a poor general health status. Diabetes mellitus was correlated with Hypogonadism in most studies, but was not established as a risk factor. Although diseases, such as coronary heart disease, hypertension, stroke, and peripheral arterial disease did not predict Hypogonadism, they did correlate with incident low T. The data reviewed on potential consequences suggest that low T levels may be linked to earlier all-cause and cardiovascular related mortality among men. This literature review suggests that men with certain factors, such as advanced age, obesity, MetS, and poor general health, are more likely to have and develop Hypogonadism. Low levels of T may have important long-term negative health consequences.
Ronald S. Swerdloff - One of the best experts on this subject based on the ideXlab platform.
-
Hypogonadotropic and Hypergonadotropic Hypogonadism
Testosterone, 2017Co-Authors: Vijaya Surampudi, Ronald S. SwerdloffAbstract:Male Hypogonadism is a clinical syndrome that results from failure of the testis to produce physiological levels of testosterone and adequate spermatogenesis as a result of disruption of one or more levels of the hypothalamic-pituitary-testicular axis. Diagnosis of Hypogonadism can be difficult given that the symptoms and signs are nonspecific and can change depending on age, comorbid illness, severity, and duration of Hypogonadism (Bhasin et al., J Clin Endocrinol Metab, 95(6):253, 2010). A thorough history and physical examination will be needed to help determine the etiology.
-
Emerging medication for the treatment of male Hypogonadism
Expert opinion on emerging drugs, 2016Co-Authors: Aydogan Aydogdu, Ronald S. SwerdloffAbstract:ABSTRACTIntroduction: Male Hypogonadism is characterized by inadequate production of Testosterone (T) (hypoandrogenism) and deficiencies in spermatogenesis. The main treatment of male Hypogonadism is T replacement therapy (TRT), but for some of the patients, alternative drugs may be more suitable.Areas covered: The available literature of T and alternative treatments for male Hypogonadism are discussed.Expert opinion: Transdermal application of T gels are the most commonly used route of T administration. Some oral T formulations are either associated with hepatic toxicity (i.e. methyltestosterone) or short half-lives that require multiple doses per day (i.e. oral testosterone undecanoate). Short acting, injectable T formulations are also available. If the patient prefers not to use daily drugs or short acting injectable formulations, depot formulations such as injectable testosterone undecanoate (TU) may be a good alternative. If the patient has hypogonadotropic Hypogonadism and desires fertility or if he...
-
Treating Hypogonadism in younger males
Expert opinion on pharmacotherapy, 2010Co-Authors: Anthony Yin, Ronald S. SwerdloffAbstract:Importance of the field: Hypogonadism in the young and middle-aged male is a well-established clinical entity. The majority of the patients have primary gonadal insufficiency with Klinefelter syndrome a common cause. Secondary Hypogonadism in these age groups can be congenital, secondary to medications, or associated with a hypothalamic–pituitary mass or inflammatory lesions. Signs and symptoms in males with Hypogonadism can include impaired sexuality, decreased muscle strength, increased body fat, decreased bone mass, impaired mood and mild anemia; in young patients puberty can be delayed. Several new treatment modalities have become available in recent years and a number of future compounds are in development.Areas covered in this review/What the reader will gain: This review explores the treatment options for children, young adult and middle-aged males with Hypogonadism related to various etiologies, including currently available and future testosterone formulations and other non-testosterone compounds...
Lawrence H. Einhorn - One of the best experts on this subject based on the ideXlab platform.
-
The effects of Hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy
Supportive Care in Cancer, 2019Co-Authors: Nityananda Khanal, N. H. Hanna, M. Kalra, Timothy E Stump, Pamela Monahan, Mary J. Brames, S. S. Ahmed, T.j. Miller, Lawrence H. EinhornAbstract:BackgroundIt is important to assess the prevalence of Hypogonadism and to identify the correlation between Hypogonadism and cancer treatment with quality of life (QoL) in germ cell tumor (GCT) survivors.MethodsThis is a single-center, non-randomized, prospective observational study in GCT survivors 18–50 years of age previously treated with surgery and chemotherapy (S+C) or surgery alone (S). Patients completed a validated QoL questionnaire at baseline, 3, and 6 months. Patients received supplemental testosterone as clinically indicated. Mean QoL scores were compared between two treatment groups (S+C vs. S) and within each group between survivors with Hypogonadism (serum testosterone level
T H Jones - One of the best experts on this subject based on the ideXlab platform.
-
systematic literature review of the risk factors comorbidities and consequences of Hypogonadism in men
Journal of Andrology, 2014Co-Authors: V Zarotsky, Mingyi Huang, W Carman, Abraham Morgentaler, Puneet K Singhal, D Coffin, T H JonesAbstract:Summary The objective of this review was to summarize the literature on the risk factors, comorbidities, and consequences of male Hypogonadism, which is defined as a syndrome complex that includes biochemical confirmation of low testosterone (T) and the consistent symptoms and signs associated with low T. A systematic literature search was performed in PubMed/MEDLINE, EMBASE, Cochrane Library for articles published in the last 10 years on risk factors, comorbidities, and consequences of male Hypogonadism. Of the 53 relevant studies identified, nine examined potential risk factors, 14 examined potential comorbidities, and 30 examined potential consequences of male Hypogonadism. Based on studies conducted in Asia, Australia, Europe, and North & South America, the important factors that predicted and correlated with Hypogonadism were advanced age, obesity, a diagnosis of metabolic syndrome (MetS), and a poor general health status. Diabetes mellitus was correlated with Hypogonadism in most studies, but was not established as a risk factor. Although diseases, such as coronary heart disease, hypertension, stroke, and peripheral arterial disease did not predict Hypogonadism, they did correlate with incident low T. The data reviewed on potential consequences suggest that low T levels may be linked to earlier all-cause and cardiovascular related mortality among men. This literature review suggests that men with certain factors, such as advanced age, obesity, MetS, and poor general health, are more likely to have and develop Hypogonadism. Low levels of T may have important long-term negative health consequences.
Jose Bessa - One of the best experts on this subject based on the ideXlab platform.
-
Compensated Hypogonadism in men with sickle cell disease.
Clinical endocrinology, 2021Co-Authors: Anna Paloma Martins Rocha Ribeiro, Caroline Santos Silva, Jean Carlos Zambrano, Juliana De Oliveira Freitas Miranda, Carlos Augusto Fernandes Molina, Cristiano Mendes Gomes, Eduardo P. Miranda, Jose BessaAbstract:OBJECTIVE To evaluate the prevalence of Hypogonadism in a population of men with SCD and characterize its aetiology. Sickle cell disease (SCD) is associated with the development of Hypogonadism, but there is still controversy regarding its aetiology and clinical implications. METHODS We performed a cross-sectional study of 34 men with SCD aged > 18 years. Sociodemographic and clinical data, including anthropometric measurements (weight, height and BMI), were obtained. Early morning, blood samples were collected and total testosterone (TT), free testosterone (FT), luteinizing hormone (LH), follicle stimulating hormone (FSH), a complete blood count and haemoglobin electrophoresis were measured. Eugonadism was defined as T ≥300 ng/dL and LH ≤9.4 mUI/mL; primary Hypogonadism as T 9.4 mUI/mL; secondary Hypogonadism as T 9.4 mUI/mL. RESULTS Median age was 33 (26-41) years, and SS genotype was the most frequent (73.5%). The prevalence of eugonadism, compensated Hypogonadism and secondary Hypogonadism was 67.5%, 26.4% and 5.88%, respectively. No men with primary Hypogonadism were identified in our sample. Those with compensated Hypogonadism had also higher FSH levels (>7.8 mUI/mL, P
